Abstract
[111In]-DTPA-D-Phe1-octreotide (OctreoScan®, Mallinkrodt) is widely used for detection of neuroendocrine tumors and has lately been proposed for radionuclide therapy. We found, using HPLC and a GF-250 column (Zorbax®, Hewlett Packard), that OctreoScan® can be separated in two radiolabeled components of about equal amount. The analytical conditions for a quantitative isolation indicate that the two-peptide components of OctreoScan® have different lipophilicity. The isolated components are stable and do not transform into each other at room temperature during 6 hours (shelf-life of OctreoScan®).
Original language | English |
---|---|
Pages (from-to) | 95-99 |
Number of pages | 5 |
Journal | Journal of Radioanalytical and Nuclear Chemistry |
Volume | 247 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2001 |
Externally published | Yes |
ASJC Scopus subject areas
- Analytical Chemistry
- Nuclear Energy and Engineering
- Radiology Nuclear Medicine and imaging
- Pollution
- Spectroscopy
- Public Health, Environmental and Occupational Health
- Health, Toxicology and Mutagenesis